Clinical Trial Detail

NCT ID NCT04300140
Title Efficacy and Safety Study of AVB-S6-500 in Patients With Clear Cell Renal Cell Carcinoma
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Aravive, Inc.
Indications

clear cell renal cell carcinoma

Therapies

AVB-S6-500 + Cabozantinib

Cabozantinib

Age Groups: adult senior

No variant requirements are available.